Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 21

1.

Rapid drug susceptibility testing with a molecular beacon assay is associated with earlier diagnosis and treatment of multidrug-resistant tuberculosis in California.

Banerjee R, Allen J, Lin SY, Westenhouse J, Desmond E, Schecter GF, Scott C, Raftery A, Mase S, Watt JP, Flood J.

J Clin Microbiol. 2010 Oct;48(10):3779-81. doi: 10.1128/JCM.01236-10. Epub 2010 Aug 11.

2.

Evaluation of seven tests for the rapid detection of multidrug-resistant tuberculosis in Uganda.

Bwanga F, Joloba ML, Haile M, Hoffner S.

Int J Tuberc Lung Dis. 2010 Jul;14(7):890-5.

PMID:
20550774
3.

Direct susceptibility testing for multi drug resistant tuberculosis: a meta-analysis.

Bwanga F, Hoffner S, Haile M, Joloba ML.

BMC Infect Dis. 2009 May 20;9:67. doi: 10.1186/1471-2334-9-67. Review.

4.

Epidemiology and treatment of multidrug resistant tuberculosis.

Mitnick CD, Appleton SC, Shin SS.

Semin Respir Crit Care Med. 2008 Oct;29(5):499-524. doi: 10.1055/s-0028-1085702. Epub 2008 Sep 22. Review.

5.

Type 2 diabetes and multidrug-resistant tuberculosis.

Fisher-Hoch SP, Whitney E, McCormick JB, Crespo G, Smith B, Rahbar MH, Restrepo BI.

Scand J Infect Dis. 2008;40(11-12):888-93. doi: 10.1080/00365540802342372.

6.

Cost-effectiveness analysis of introduction of rapid, alternative methods to identify multidrug-resistant tuberculosis in middle-income countries.

Acuna-Villaorduna C, Vassall A, Henostroza G, Seas C, Guerra H, Vasquez L, Morcillo N, Saravia J, O'Brien R, Perkins MD, Cunningham J, Llanos-Zavalaga L, Gotuzzo E.

Clin Infect Dis. 2008 Aug 15;47(4):487-95. doi: 10.1086/590010.

PMID:
18636955
7.

Programmatic implementation of rapid DST for Mycobacterium tuberculosis in Peru.

Asencios L, Yale G, Yagui M, Quispe N, Taylor A, Blaya J, Contreras C, Cegielski P, Bayona J, Bonilla C, Shin S.

Int J Tuberc Lung Dis. 2008 Jul;12(7):743-9.

PMID:
18544198
8.

Scale-up of multidrug-resistant tuberculosis laboratory services, Peru.

Shin SS, Yagui M, Ascencios L, Yale G, Suarez C, Quispe N, Bonilla C, Blaya J, Taylor A, Contreras C, Cegielski P.

Emerg Infect Dis. 2008 May;14(5):701-8. doi: 10.3201/eid1405.070721.

9.

The nitrate reductase assay for the rapid detection of isoniazid and rifampicin resistance in Mycobacterium tuberculosis: a systematic review and meta-analysis.

Martin A, Panaiotov S, Portaels F, Hoffner S, Palomino JC, Angeby K.

J Antimicrob Chemother. 2008 Jul;62(1):56-64. doi: 10.1093/jac/dkn139. Epub 2008 Apr 10. Review.

PMID:
18407918
10.

A web-based laboratory information system to improve quality of care of tuberculosis patients in Peru: functional requirements, implementation and usage statistics.

Blaya JA, Shin SS, Yagui MJ, Yale G, Suarez CZ, Asencios LL, Cegielski JP, Fraser HS.

BMC Med Inform Decis Mak. 2007 Oct 28;7:33.

11.

Timely diagnosis of MDR-TB under program conditions: is rapid drug susceptibility testing sufficient?

Yagui M, Perales MT, Asencios L, Vergara L, Suarez C, Yale G, Salazar C, Saavedra M, Shin S, Ferrousier O, Cegielski P.

Int J Tuberc Lung Dis. 2006 Aug;10(8):838-43.

PMID:
16898366
12.
13.

Validation of a rapid method for detection of M. tuberculosis resistance to isoniazid and rifampin in Lima, Peru.

Solis LA, Shin SS, Han LL, Llanos F, Stowell M, Sloutsky A.

Int J Tuberc Lung Dis. 2005 Jul;9(7):760-4.

PMID:
16013771
14.

Comparative evaluation of the nitrate reduction assay, the MTT test, and the resazurin microtitre assay for drug susceptibility testing of clinical isolates of Mycobacterium tuberculosis.

Montoro E, Lemus D, Echemendia M, Martin A, Portaels F, Palomino JC.

J Antimicrob Chemother. 2005 Apr;55(4):500-5. Epub 2005 Feb 24.

PMID:
15731200
15.

Community-based therapy for multidrug-resistant tuberculosis in Lima, Peru.

Mitnick C, Bayona J, Palacios E, Shin S, Furin J, Alcántara F, Sánchez E, Sarria M, Becerra M, Fawzi MC, Kapiga S, Neuberg D, Maguire JH, Kim JY, Farmer P.

N Engl J Med. 2003 Jan 9;348(2):119-28.

16.

Feasibility and cost-effectiveness of standardised second-line drug treatment for chronic tuberculosis patients: a national cohort study in Peru.

Suárez PG, Floyd K, Portocarrero J, Alarcón E, Rapiti E, Ramos G, Bonilla C, Sabogal I, Aranda I, Dye C, Raviglione M, Espinal MA.

Lancet. 2002 Jun 8;359(9322):1980-9.

PMID:
12076553
17.
18.
19.

Infection and disease among household contacts of patients with multidrug-resistant tuberculosis.

Teixeira L, Perkins MD, Johnson JL, Keller R, Palaci M, do Valle Dettoni V, Canedo Rocha LM, Debanne S, Talbot E, Dietze R.

Int J Tuberc Lung Dis. 2001 Apr;5(4):321-8.

PMID:
11334250
20.

Using treatment failure under effective directly observed short-course chemotherapy programs to identify patients with multidrug-resistant tuberculosis.

Becerra MC, Freeman J, Bayona J, Shin SS, Kim JY, Furin JJ, Werner B, Sloutsky A, Timperi R, Wilson ME, Pagano M, Farmer PE.

Int J Tuberc Lung Dis. 2000 Feb;4(2):108-14.

PMID:
10694087

Supplemental Content

Support Center